ATE430936T1 - Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome - Google Patents

Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome

Info

Publication number
ATE430936T1
ATE430936T1 AT05819706T AT05819706T ATE430936T1 AT E430936 T1 ATE430936 T1 AT E430936T1 AT 05819706 T AT05819706 T AT 05819706T AT 05819706 T AT05819706 T AT 05819706T AT E430936 T1 ATE430936 T1 AT E430936T1
Authority
AT
Austria
Prior art keywords
cyfra
osteopontin
markers
colorectal cancer
colorectal carcinoma
Prior art date
Application number
AT05819706T
Other languages
English (en)
Inventor
Werner Zolg
Wolfgang Rollinger
Veit Grunert
Herbert Andres
Johann Karl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE430936T1 publication Critical patent/ATE430936T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4742Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05819706T 2004-12-23 2005-12-22 Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome ATE430936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04030619 2004-12-23
PCT/EP2005/013867 WO2006066915A1 (en) 2004-12-23 2005-12-22 Use of cyfra 21-1 as a marker for colorectal cancer

Publications (1)

Publication Number Publication Date
ATE430936T1 true ATE430936T1 (de) 2009-05-15

Family

ID=34927964

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05819706T ATE430936T1 (de) 2004-12-23 2005-12-22 Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome

Country Status (9)

Country Link
US (1) US7731938B2 (de)
EP (1) EP1831695B1 (de)
JP (1) JP4606469B2 (de)
CN (2) CN101088012A (de)
AT (1) ATE430936T1 (de)
CA (1) CA2585788C (de)
DE (1) DE602005014386D1 (de)
ES (1) ES2325277T3 (de)
WO (1) WO2006066915A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2059813A2 (de) * 2006-06-26 2009-05-20 Technion Research & Development Foundation LTD. Verfahren und kits zur krebsdiagnose
CA2655851A1 (en) * 2006-08-01 2008-02-07 F. Hoffmann-La Roche Ag Use of nnmt as a marker for lung cancer
US20100196889A1 (en) * 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CA2728153C (en) 2008-07-03 2015-01-27 F. Hoffmann-La Roche Ag Asc as a marker for lung cancer
US9075060B2 (en) * 2009-06-16 2015-07-07 Technion Research & Development Foundation Limited Methods for diagnosing oral or oral-pharyngeal cancer
US20130095503A1 (en) * 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
CN106706914B (zh) 2010-09-09 2018-10-19 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及单克隆抗体
EP2684051B1 (de) 2011-03-11 2016-04-27 Roche Diagniostics GmbH Asc als marker für die chronisch obstruktive lungenerkrankung (copd)
WO2013160807A1 (en) * 2012-04-24 2013-10-31 Sahillioglu Ali Can A method for antigen delivery
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 asc 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
EP3183578B8 (de) * 2014-08-22 2020-07-15 Abbott Laboratories Verfahren zur früherkennung von kolorektalkarzinom
US20200339670A1 (en) * 2017-12-20 2020-10-29 Michael Heneka Novel means and methods for treating neurodegenerative diseases
AU2019252672B2 (en) 2018-04-12 2025-08-14 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
KR102293271B1 (ko) * 2019-02-25 2021-08-23 가톨릭대학교 산학협력단 Cyfra 21-1을 이용한 갑상선암 림프절 전이 진단 방법
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
WO2021185982A1 (en) * 2020-03-19 2021-09-23 Advanced Marker Discovery S.l. Protein signature for screening general population for colorectal cancer and/or pre-cancerous stage thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165740A (en) * 1998-09-30 2000-12-26 Sysmex Corporation Method and device for flow-cytometric microorganism analysis
US7118912B2 (en) * 2002-08-26 2006-10-10 Case Western Reserve University Methods and compositions for categorizing patients
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Timp1を用いた検出方法
MXPA05006382A (es) * 2002-12-20 2005-10-24 Hoffmann La Roche Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
CN100504393C (zh) * 2003-05-26 2009-06-24 霍夫曼-拉罗奇有限公司 蛋白masp的特异性结合试剂在制备诊断试剂中的用途

Also Published As

Publication number Publication date
WO2006066915A1 (en) 2006-06-29
HK1115636A1 (en) 2008-12-05
EP1831695B1 (de) 2009-05-06
US20080020414A1 (en) 2008-01-24
EP1831695A1 (de) 2007-09-12
DE602005014386D1 (de) 2009-06-18
JP4606469B2 (ja) 2011-01-05
ES2325277T3 (es) 2009-08-31
JP2008522172A (ja) 2008-06-26
CN101088012A (zh) 2007-12-12
CA2585788C (en) 2013-03-05
US7731938B2 (en) 2010-06-08
CN101088011A (zh) 2007-12-12
CA2585788A1 (en) 2006-06-29
CN101088011B (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE554389T1 (de) Apex als marker für lungenkrebs
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
WO2009074276A3 (en) Marker panel for colorectal cancer
DE602005013225D1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
CY1122022T1 (el) Αναπτυξη και χρηση φθοριζοντων ανιχνευτων αδεσμευτης χολερυθρινης
DE60332639D1 (de) Verwendung von biomarkern zum nachweis von eierstockkrebs
ATE449865T1 (de) Teststreifen zum analytnachweis und verwendungsverfahren
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE527543T1 (de) Testvorrichtung zur schnelldiagnose
ATE513216T1 (de) Verwendung des proteins satb2 als prognostischer marker für kolorektalkarzinome
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602007004570D1 (de) Verwendung von Nogo-C bei der Beurteilung von Herzversagen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1831695

Country of ref document: EP